These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 4878452)

  • 1. [The level of p-aminosalicyclic acid in the blood in oral treatment with a calcium-aluminum-p-aminosalicylate].
    Mulder RJ; Huizinga T
    Ned Tijdschr Geneeskd; 1968 Sep; 112(37):1630-4. PubMed ID: 4878452
    [No Abstract]   [Full Text] [Related]  

  • 2. [Studies on the metabolism of para-aminosalicylic acid in the body. IV. Effect of sodium salt of para-animosalicylic acid administered orally in coated tablets soluble in the intestine on the bacteriostatic level and on drug tolerance].
    Hornung S; Nilodemowicz E; Owsiński J; Rapf T
    Gruzlica; 1967 Jul; 35(7):657-64. PubMed ID: 4865322
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of the metabolism of p-aminosalicylic acid (PAS) in the treatment of tuberculosis. Interaction with the metabolism of isonicotinic acid hydrazide (INH) and the synthesis of cholesterol.
    Lehmann J
    Scand J Respir Dis; 1969; 50(3):169-85. PubMed ID: 5195904
    [No Abstract]   [Full Text] [Related]  

  • 4. Bioavailability of aminosalicylic acid and its various salts in humans IV: comparison of four brands of the sodium salt.
    Pentikäinen PJ; Wan SH; Azarnoff DL
    J Pharm Sci; 1974 Sep; 63(9):1431-4. PubMed ID: 4610119
    [No Abstract]   [Full Text] [Related]  

  • 5. [Metabolism of PASA during administration of the preparation once and thrice daily].
    Savula MM
    Probl Tuberk; 1967; 45(4):70-4. PubMed ID: 5606807
    [No Abstract]   [Full Text] [Related]  

  • 6. Bioavailability studies on p-aminosalicylic acid and its various salts in man. II. Comparison of parasal and pascorbic.
    Pentikainen P; Wan SH; Azarnoff DL
    Am Rev Respir Dis; 1973 Dec; 108(6):1340-70. PubMed ID: 4751720
    [No Abstract]   [Full Text] [Related]  

  • 7. Importance of the type of dosage form and saturable acetylation in determining the bioactivity of p-aminosalicylic acid.
    Wagner JG; Holmes PD; Wilkinson PK; Blair DC; Stoll RG
    Am Rev Respir Dis; 1973 Sep; 108(3):536-46. PubMed ID: 4745249
    [No Abstract]   [Full Text] [Related]  

  • 8. [The para-aminosalicylic acid (PAS) level of the venous blood in patients after the administration of various PAS preparations for pulmonary tuberculosis].
    Kreukniet J; Tasman A; Bangma PJ
    Ned Tijdschr Geneeskd; 1965 Sep; 109(38):1760-1. PubMed ID: 5317952
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of the lymphatics in the intestinal absorption and distribution of drugs.
    De Marco TJ; Levine RR
    J Pharmacol Exp Ther; 1969 Sep; 169(1):142-51. PubMed ID: 4979680
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
    Sandborn WJ; Hanauer SB; Buch A
    Aliment Pharmacol Ther; 2004 May; 19(10):1089-98. PubMed ID: 15142198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Administration by slow phleboclysis of isoniazid and para-aminosalicylic acid in the treatment of tuberculosis. Therapeutic effects and blood levels of the drug].
    Mariani B; Bisetti A; Monzali G
    G Ital Mal Torace; 1967; 21(2):81-92. PubMed ID: 5602966
    [No Abstract]   [Full Text] [Related]  

  • 12. Delivery of 5-aminosalicylate to the guinea pig cecum.
    Salata K; Dull BJ; Goldman P
    Biochem Pharmacol; 1987 Jan; 36(2):295-7. PubMed ID: 3814172
    [No Abstract]   [Full Text] [Related]  

  • 13. [Study of the stability and quality of phenol type preparations for injections. II. Method of preparing a stable solution of sodium para-aminosalicylate].
    Rybachuk DV; Konev FA; Kurchenko IN
    Farm Zh; 1978; (4):87-9. PubMed ID: 689165
    [No Abstract]   [Full Text] [Related]  

  • 14. [Oral therapy instead of enemas].
    MMW Fortschr Med; 2003 Feb; 145(8):56. PubMed ID: 12661449
    [No Abstract]   [Full Text] [Related]  

  • 15. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
    Rasmussen SN; Bondesen S; Hvidberg EF; Hansen SH; Binder V; Halskov S; Flachs H
    Gastroenterology; 1982 Nov; 83(5):1062-70. PubMed ID: 7117789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of aminosalicylic acid and its various salts in humans. 3. Absorption from tablets.
    Wan SH; Pentikainen PJ; Azarnoff DL
    J Pharm Sci; 1974 May; 63(5):708-11. PubMed ID: 4829991
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative evaluation of blood levels and tolerance of sodium PAS and conjugated PAS and ascorbic acid.
    Schless JM; Inglis RM; Hammond JH; Hale JM
    Dis Chest; 1966 Dec; 50(6):595-600. PubMed ID: 5964864
    [No Abstract]   [Full Text] [Related]  

  • 18. [Blood concentration of PAS with different doses and methods of administration].
    Korotaev GA; Kozulitsyna TI; Vasil'eva ZS
    Ter Arkh; 1971 Jan; 43(1):37-40. PubMed ID: 5574533
    [No Abstract]   [Full Text] [Related]  

  • 19. 5-Aminosalicylic acid enemas in patients with active ulcerative colitis. Influence of acidity on the kinetic pattern.
    Bondesen S; Nielsen OH; Jacobsen O; Rasmussen SN; Hansen SH; Halskov S; Binder V; Hvidberg EF
    Scand J Gastroenterol; 1984 Jul; 19(5):677-82. PubMed ID: 6382570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady state disposition of 5-aminosalicyclic acid following oral dosing.
    Klotz U; Stracciari GL
    Arzneimittelforschung; 1993 Dec; 43(12):1357-9. PubMed ID: 8141827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.